1. Home
  2. OOMA vs ARVN Comparison

OOMA vs ARVN Comparison

Compare OOMA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ooma Inc.

OOMA

Ooma Inc.

SELL

Current Price

$19.16

Market Cap

548.1M

Sector

Technology

ML Signal

SELL

Logo Arvinas Inc.

ARVN

Arvinas Inc.

SELL

Current Price

$7.44

Market Cap

600.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OOMA
ARVN
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
548.1M
600.2M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
OOMA
ARVN
Price
$19.16
$7.44
Analyst Decision
Strong Buy
Buy
Analyst Count
7
15
Target Price
★ $26.80
$14.46
AVG Volume (30 Days)
285.0K
★ 768.5K
Earning Date
12-07-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 188.46
58.84
EPS
0.20
★ 0.88
Revenue
$114,490,000.00
★ $262,600,000.00
Revenue This Year
$21.68
$5.49
Revenue Next Year
$4.82
N/A
P/E Ratio
$94.28
★ $4.12
Revenue Growth
★ 9.53
N/A
52 Week Low
$9.79
$6.74
52 Week High
$26.19
$14.22

Technical Indicators

Market Signals
Indicator
OOMA
ARVN
Relative Strength Index (RSI) 32.80 41.00
Support Level $16.42 $6.74
Resistance Level $19.56 $7.77
Average True Range (ATR) 0.67 0.41
MACD -0.02 0.05
Stochastic Oscillator 5.36 24.19

Price Performance

Historical Comparison
OOMA
ARVN

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: